Nature Reviews Drug Discovery contents October 2012 Volume 11 Number 10 pp 731-812

TABLE OF CONTENTS
October 2012 Volume 11 Number 10
Impact Factor 29.008 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month Article series: A guide to drug discovery  Featured article: Targeting the TGFβ signalling pathway in disease Rosemary J. Akhurst & Akiko Hata
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
The Encyclopedia of DNA Elements 30 papers published simultaneously in Nature, Genome Research and Genome Biology. Access videos, Features and the collected research papers, and explore the thematic threads that run through them via the Nature ENCODE explorer or the NatureENCODE app. Produced with support from Illumina
In this issue p731 | doi:10.1038/nrd3848 Full Text
Comment: In search of preclinical robustness Ian S. Peers, Peter R. Ceuppens & Chris Harbron p733 | doi:10.1038/nrd3849 Systematic engagement of statisticians in preclinical research could help address the weaknesses that are undermining the likelihood of subsequent success in drug discovery and development. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Economists propose a US$30 billion boost to biomedical R&D Asher Mullard 735 | doi:10.1038/nrd3857 Economists hope they can attract billions of dollars for drug R&D by securitizing research projects. Could they close the innovation gap in the process? PDF
Moving from an asthma pipe dream to a pipeline Dave Holmes p737 | doi:10.1038/nrd3858 After decades of stubbornly slow progress in asthma drug development, recent results from a trial of GlaxoSmithKline's mepolizumab hint at a brighter future. PDF
NEWS IN BRIEF AstraZeneca and Bayer share their entire compound libraries | Total drug development timelines are getting shorter | Cytoskeletal motor protein researchers win Lasker award p739 | doi:10.1038/nrd3865 PDF
BIOBUSINESS BRIEFS Trial watch: Dual-acting combination meets heart failure end point Sarah Crunkhorn p740 | doi:10.1038/nrd3855 PDF
BIOBUSINESS BRIEFS Market watch: Upcoming market catalysts in Q4 2012 John Tucker p740 | doi:10.1038/nrd3856 PDF
PATENT WATCH Myriad revisited still upholds DNA patenting | Claims are key to obviousness-type double patenting | Targeting T helper 17 cells and interleukin-17 Charlotte Harrison p742 | doi:10.1038/nrd3866 PDF
AN AUDIENCE WITH Michael Snyder p744 | doi:10.1038/nrd3867 Michael Snyder, Director of Stanford Center for Genomics and Personalized Medicine, discusses how the ENCODE project could impact drug discovery. PDF
FROM THE ANALYST'S COUCH Autism spectrum disorders Sarah Nightingale p745 | doi:10.1038/nrd3771 The developmental pipeline for drugs to treat autism spectrum disorders (ASDs) has more than doubled since April last year, and each candidate in clinical development targets a different mechanism of action. This article investigates the ASD market and provides an overview of experimental therapies. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative disease: EPHA4 inhibition rescues neurodegeneration in ALS p747 | doi:10.1038/nrd3853 PDF Neurodegenerative diseases: Anti-epileptic drug shows benefit in AD mouse model p748 | doi:10.1038/nrd3850 PDF Vaccines: Self-amplifying RNA in lipid nanoparticles: a next-generation vaccine? p748 | doi:10.1038/nrd3854 PDF Metabolic disorders: Safe cannabinoid receptor modulators in sight? p749 | doi:10.1038/nrd3851 PDF Inflammatory disorders: Separating good from bad p750 | doi:10.1038/nrd3852 PDF IN BRIEF Cancer: A new target in Burkitt's lymphoma | Epigenetic targets: Towards a male contraceptive? | Anticancer drugs: Tumour delivery of RNA interference | Antiviral drugs: Protection against influenza B infection PDF Drug Discovery JOBS of the week Post-Doctoral (W Wang) Differentiation of iPS cells and iPSC-derived cell-based diseasing modeling and drug discovery Oklahoma Medical Research Foundation (OMRF) Drug Discovery Opportunities D. E. Shaw Research, LLC Scientist - Pre Clinical / Clinical Research, Drug Discovery, Toxicology, ADMET, DMPK Spectra Resourcing Limited Scientist / Sr Scientist – Oncology Drug Discovery H3 Biomedicine Drug Discovery Researcher Monash University More Science jobs from Drug Discovery EVENT Comprehensive Overview of FDA Regulatory Compliance for Drug and Biotech Products 25.-26.10.12 PA, US More science events from
PERSPECTIVES		Top
OPINION Article series: A guide to drug discovery The determination and interpretation of the therapeutic index in drug development Patrick Y. Muller & Mark N. Milton p751 | doi:10.1038/nrd3801 The therapeutic index of drug candidates — a quantitative relationship between their safety and efficacy, such as the ratio of the highest exposure to a drug that does not cause toxicity to the exposure that has the desired pharmacological effects — is widely used to aid decision-making in drug discovery and development. Muller and Milton discuss key issues in the calculation and interpretation of therapeutic indices at different stages of the process. Abstract | Full Text | PDF | Supplementary information
Advertisement
Knome provides researchers and clinics with human whole genome interpretation software and services. Visit www.knome.com to learn how we can help you identify the variants, genes, and gene sets that underlie disease and drug response.
REVIEWS		Top
Targeting IL-17 and TH17 cells in chronic inflammation Pierre Miossec & Jay K. Kolls p763 | doi:10.1038/nrd3794 This Review highlights the role of T helper 17 (TH17) cells and interleukin-17 (IL-17) in the pathogenesis of inflammatory diseases, and discusses key advances and challenges in targeting IL-17 in disorders such as psoriasis, rheumatoid arthritis and ankylosing spondylitis. Abstract | Full Text | PDF
Bacterial proteolytic complexes as therapeutic targets Ravikiran M. Raju, Alfred L. Goldberg & Eric J. Rubin p777 | doi:10.1038/nrd3846 Bacterial degradative proteases are essential for growth and survival, representing attractive targets for the development of novel antibacterials. However, despite pharmaceutical successes with protease modulators in several diseases, this class of enzymes has not yet been targeted to treat bacterial infections. Here, Rubin and colleagues review the biological roles of key prokaryotic degradative proteases, highlighting recent advances and challenges in their therapeutic exploitation. Abstract | Full Text | PDF
Targeting the TGFβ signalling pathway in disease Rosemary J. Akhurst & Akiko Hata p790 | doi:10.1038/nrd3810 The transforming growth factor-β (TGFβ) signalling pathway is implicated in a variety of disorders, including cancer, fibrosis and inflammation, and has become an attractive target for drug development. Here, Akhurst and Hata present therapeutic strategies for intervening in this pathway and discuss agents currently under investigation while addressing the associated challenges in their development and application. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Connecting the dots in translational research Jonathan D. Kahn p811 | doi:10.1038/nrd3357-c2 Full Text | PDF
Advertisement
New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management Click here for more information on Alzheimer's partnering opportunities.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.